Trial record 1 of 2 for:    Hepatocellular Carcinoma GenSpera
Previous Study | Return to List | Next Study

Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma (G-202-003)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01777594
Recruitment Status : Completed
First Posted : January 29, 2013
Last Update Posted : August 23, 2016
Information provided by (Responsible Party):
GenSpera, Inc.

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : March 2015
  Actual Study Completion Date : March 2015
  Certification/Extension First Submitted : August 18, 2016